Semaglutide Dosing Protocol: GLP-1 Research Guide

Moreover, possible applications in protection from infections and anti-aging properties are discussed. Semaglutide enhancement of the core molecular mechanisms involved in the progress of obesity and diabetes, although mostly preclinical, may provide a framework for future research applications in human diseases overall.

Limitations: No placebo control reported. Review article — no new primary data.

Further studies can assess if there is a need to modify pre-operative guidelines to account for patient using semaglutide and how delayed gastric emptying and constitpation will affect surgical outcomes and complications. While semaglutide therapy for diabetes mellitus has been established, there is a need for extensive research on repurposing semaglutide in neurodegenerative disease treatment.

Limitations: No placebo control reported.

Its safety profile is generally favorable, though gastrointestinal side effects can occur.By addressing multiple interconnected conditions, semaglutide is poised to transform care for patients at high risk of heart, kidney, and metabolic complications. Further research is exploring new dosing methods, combinations with other medications, and expanded use in non-diabetic populations to maximize its benefits.

Limitations: No placebo control reported. Review article — no new primary data.

The association of NAION with small, crowded discs, optic disc oedema and peripapillary exudation suggests that semaglutide-related NAION may result from changes in perfusion that lead to venous dilation and, presumably, to venous congestion during relative hypoglycaemia. Given the retrospective nature of the epidemiological studies, causality cannot be inferred, but a cautious approach to the use of semaglutide and other powerful glycaemia-reducing agents seems warranted, particularly in patients with crowded optic discs, a characteristic that can be identified by proactive eye examination for disc-at-risk characteristics by the use of optical coherence tomography.

Limitations: Review article — no new primary data.

Among 16 827 patients, 710 had T2D (194 prescribed semaglutide; 516 prescribed non-GLP-1 RA antidiabetic medications; median [IQR] age, 59 [49-68] years; 369 [52%] female) and 979 were overweight or obese (361 prescribed semaglutide; 618 prescribed non-GLP-1 RA weight-loss medications; median [IQR] age, 47 [32-59] years; 708 [72%] female). In the population with T2D, 17 NAION events occurred in patients prescribed semaglutide vs 6 in the non-GLP-1 RA antidiabetes cohort.

Limitations: No placebo control reported.

Six studies with 1,541 overweight or obese adults were included, and significant weight reductions were observed primarily due to fat mass loss. While the lean mass remained stable in some cases, notable reductions ranging from almost 0% to 40% of total weight reduction were observed in others.

Limitations: Review article — no new primary data.

Semaglutide has a predictable pharmacokinetic profile with a long t1/2 that allows for once-weekly subcutaneous administration. The AUC and Cmax of both oral and subcutaneous semaglutide increased with dose.

Limitations: No placebo control reported. Review article — no new primary data.

Doxorubicin-induced cardiotoxicity is an established model to study cardiac function. Cardiac function was studied by transthoracic echocardiography and invasive hemodynamic monitoring.

Limitations: No placebo control reported.

A total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA1c (mean difference -21.61 mmol/mol [-1.96%]) followed by tirzepatide 10 mg (-20.19 mmol/mol [-1.84%]), semaglutide 2.0 mg (-17.74 mmol/mol [-1.59%]), tirzepatide 5 mg (-17.60 mmol/mol [-1.60%]), semaglutide 1.0 mg (-15.25 mmol/mol [-1.39%]) and semaglutide 0.5 mg (-12.00 mmol/mol [-1.09%]).

Limitations: Review article — no new primary data.

Semaglutide, as a once weekly subcutaneous injection for weight management, effectively reduces body mass index (BMI) while improving hyperglycemia, elevated alanine aminotransferase levels, hyperlipidemia, and quality of life in youth with obesity. As of this review, only one large randomized clinical trial of semaglutide in youth has been completed, with a follow-up duration of 68 weeks.

Limitations: No placebo control reported. Review article — no new primary data.

Semaglutide was associated with significantly reduced risk for first-time AD diagnosis, most strongly compared with insulin (hazard ratio [HR], 0.33 [95%.

Limitations: No placebo control reported.

The model found that ESG was more cost-effective than semaglutide over a 5-year time horizon, with an ICER of -$595 532/QALY. Endoscopic sleeve gastroplasty added 0.06 QALYs and reduced total cost by $33 583 relative to semaglutide.

Limitations: No placebo control reported. Case study — cannot establish causation.

In addition, semaglutide also improved the integrity of gut barrier and altered gut microbiota, especially Alloprevotella, Alistpes, Ligilactobacillus and Lactobacillus. In summary, our findings validate that semaglutide induces modifications in the composition of the gut microbiota and ameliorates NAFLD, positioning it as a promising therapeutic candidate for addressing hepatic steatosis and associated inflammation.

Limitations: Animal study only — human translation uncertain.

Twenty-one eligible trials of semaglutide, including 34,721 patients, were identified and considered eligible for the analyses. Globally, semaglutide therapy was not associated with an increased risk of acute pancreatitis (OR 0.7; 95% CI 0.5-1.2, I2 0%).

Limitations: Review article — no new primary data.

A total of 23 studies met the inclusion criteria with a combined sample size of 57,911 participants. The meta-analysis revealed that the adverse event associated with semaglutide is gastrointestinal in nature (nausea and vomiting).

Limitations: Review article — no new primary data.

This Medical News article discusses chronic weight management with semaglutide, sold under the brand names Ozempic and Wegovy.

Limitations: No placebo control reported.

Whether and to which extent the effect is direct is still a matter of debate and an intriguing topic to investigate for suitable preventative and rehabilitative purposes. In this minireview, we will summarize the available data and suggest guidelines for a comprehensive semaglutide clinical utilization until new evidence becomes available.

Limitations: No placebo control reported. Review article — no new primary data.

This shift marks a transformative approach to obesity management and CVD prevention. However, further research is needed to fully comprehend semaglutide's cardiovascular benefits and potential risks.

Limitations: Review article — no new primary data.

Semaglutide increased sIPSC frequency in CeA and ILC neurons from alcohol-naive rats, suggesting enhanced GABA release, but had no overall effect on GABA transmission in alcohol-dependent rats. In conclusion, the GLP-1 analogue semaglutide decreased alcohol intake across different drinking models and species and modulated central GABA neurotransmission, providing support for clinical testing of semaglutide as a potentially novel pharmacotherapy for AUD.

Limitations: Animal study only — human translation uncertain.

In male and female rats, acute and repeated semaglutide administration reduced alcohol intake and prevented relapse-like drinking. Moreover, fluorescently labelled semaglutide was detected in NAc of alcohol-drinking male and female rats.

Limitations: Animal study only — human translation uncertain.

Semaglutide and pregnancy. (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023)

Limitations: No placebo control reported.

In conclusion, semaglutide inhibits I/R injury-induced cardiomyocyte apoptosis by activating the PKG/PKCε/ERK1/2 pathway. The beneficial effect of GLP-1/GLP-1R, involved in the activation of the PKG/PKCε/ERK1/2 pathway, may provide a novel treatment method for myocardial I/R injury.

Limitations: Animal study only — human translation uncertain.

Among the different regions of the brain, semaglutide concentrations were significantly higher in the hypothalamus. The analytical method and pharmacokinetic information may be helpful toward a better understanding of the effect of semaglutide in the brain and further development of GLP-1 analogs for various brain diseases.

Limitations: Animal study only — human translation uncertain.

In participants completing the Control of Eating Questionnaire (semaglutide, n&#xa0;=&#xa0;88; placebo, n&#xa0;=&#xa0;86), mean body weight changes were&#x2009;-14.8% (semaglutide) and&#x2009;-2.4% (placebo). Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p&#x2009;<&#x2009;0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p&#x2009;<&#x2009;0.05); and for hunger and fullness at week 20 (p&#x2009;<&#x2009;0.001).

Limitations: Standard limitations apply. Check original paper for full discussion.

The most common adverse events reported in STEP 1-5 were gastrointestinal events, which were transient, mild-to-moderate in severity, and typically resolved without permanent treatment discontinuation. This article reviews the data from STEP 1-5 and highlights clinically relevant findings for primary care providers.

Limitations: Review article — no new primary data.

Due to its potent glucose-lowering effect, patients at risk for deterioration of existing DRP should be carefully monitored if treated with semaglutide, particularly if also treated with insulin. Given the beneficial metabolic and cardiovascular actions of semaglutide, and the low risk for severe adverse events, semaglutide has an overall favorable risk/benefit profile for patient with type 2 diabetes.

Limitations: No placebo control reported. Review article — no new primary data.

Trial data and other pertinent articles were obtained via database search through the US National Library of Medicine Clinical Trials and the National Center for Biotechnology Information. All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss.

Limitations: Review article — no new primary data.

The study included 4 randomized controlled trials having a total of 3,613 individuals with obesity without diabetes. The mean difference for weight reduction was -11.85%, favoring semaglutide [95% confidence interval (CI) (-12.81,-10.90), p<0.00001].

Limitations: Review article — no new primary data.

Between Jan 21, 2019 and June 4, 2019, 437 participants were screened, of whom 401 were randomly assigned to semaglutide 2&#xb7;4 mg (n=199), semaglutide 1&#xb7;7 mg (n=101), or placebo (n=101) and included in the intention-to-treat analysis. Estimated mean change in bodyweight from baseline to week 68 was -13&#xb7;2% (SEM 0&#xb7;5) in the semaglutide 2&#xb7;4 mg group and -9&#xb7;6% (0&#xb7;8) in the semaglutide 1&#xb7;7 mg group versus -2&#xb7;1% (0&#xb7;8) in the placebo group (estimated treatment difference [ETD] -11&#xb7;1 percentage points [95% CI -12&#xb7;9 to -9&#xb7;2] for semaglutide 2&#xb7;4 mg vs placebo; -7&#xb7;5 percentage points [95% CI -9&#xb7;6 to -5&#xb7;4] for semaglutide 1&#xb7;7 mg vs placebo; both p<0&#xb7;0001).

Limitations: Standard limitations apply. Check original paper for full discussion.

The mice body weight, liver weight, blood glucose, TG, TCHO, LDL and pro-inflammatory factors were significantly reduced after semaglutide. Meanwhile, semaglutide increased the SOD level.

Limitations: Animal study only — human translation uncertain.

Semaglutide offers the benefits of a highly effective GLP-1RA in both injectable and oral formulations. Selection of the most appropriate formulation can be made on an individual basis to best suit the patient's preferences and needs.

Limitations: No placebo control reported. Review article — no new primary data.

GI AEs were more common with semaglutide 2.4&#xa0;mg than placebo, with most frequently nausea (43.9% vs. 16.1% of participants), diarrhoea (29.7% vs.

Limitations: Standard limitations apply. Check original paper for full discussion.

After Semaglutide treatment, the food intake and body weight of mice were evidently decreased, while the relative gastrocnemius weight ratio were conversely increased. Meanwhile, the levels of TG, CHO, LDL, HDL, TNF-&#x3b1;, IL-6, IL-1&#x3b2; and HOMA-IR were all observed to decrease remarkably after Semaglutide intervention.

Limitations: Animal study only — human translation uncertain.

A total of 23 randomized trials involving 22,096 patients with T2DM were included. There were 730 incident DR cases-463 in the semaglutide group and 267 in the control group.

Limitations: Review article — no new primary data.

From June 4 to Nov 14, 2018, 1595 patients were screened, of whom 1210 were randomly assigned to semaglutide 2&#xb7;4 mg (n=404), semaglutide 1&#xb7;0 mg (n=403), or placebo (n=403) and included in the intention-to-treat analysis. Estimated change in mean bodyweight from baseline to week 68 was -9&#xb7;6% (SE 0&#xb7;4) with semaglutide 2&#xb7;4 mg vs -3&#xb7;4% (0&#xb7;4) with placebo.

Limitations: Standard limitations apply. Check original paper for full discussion.

Transcriptomic analysis of microdissected brain areas from semaglutide-treated rats showed upregulation of prolactin-releasing hormone and tyrosine hydroxylase in the area postrema. We suggest semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.

Limitations: Animal study only — human translation uncertain.

The area under the concentration-time curve (AUC) for paracetamol 0 to 5 hours after a standardized meal (AUC0-5h,para ; primary endpoint) was increased by 8% (P =&#x2009;0.005) with semaglutide 2.4 mg versus placebo at week 20 (non-significant when corrected for week 20 body weight; P =&#x2009;0.12). No effect was seen on AUC0-1h,para , maximum observed paracetamol concentration, or time to maximum observed paracetamol concentration.

Limitations: Standard limitations apply. Check original paper for full discussion.

The model accurately described concentration profiles across trials. Post-dose fasting time, co-ingestion of a large water volume, and body weight were the most important covariates affecting semaglutide exposure.

Limitations: No placebo control reported.

Between June 19 and Nov 28, 2019, of 1515 adults assessed for eligibility, 961 participants (mean age 58&#xb7;0 years [SD 10&#xb7;0]; 398 [41%] women) were included. Participants were randomly assigned to once-weekly semaglutide 2&#xb7;0 mg (n=480 [50%]) or 1&#xb7;0 mg (n=481 [50%]); 462 (96%) patients in the semaglutide 2&#xb7;0 mg group and 471 (98%) in the semaglutide 1&#xb7;0 mg group completed the trial.

Limitations: No placebo control reported.

Furthermore, the development of an oral formulation for semaglutide may provide individuals with additional benefits in relation to treatment adherence. In addition to T2D, liraglutide is used in the treatment of obesity, while semaglutide is currently under investigation for use in obesity and NASH.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

Clinical development for obesity, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease is underway worldwide. This article summarizes the milestones in the development of semaglutide leading to this first approval for type 2 diabetes.

Limitations: No placebo control reported. Review article — no new primary data.

A total of 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide were included. We identified only 1 trial with oral semaglutide.

Limitations: Review article — no new primary data.

Semaglutide can be another acceptable option for patients with T2DM, and it has a potential role among patients who require weight loss with a low risk of hypoglycemia. This article evaluates the pharmacokinetics of semaglutide and summarizes its application to clinical practice based on efficacy and safety data.

Limitations: Review article — no new primary data.

Between February 3, 2014, and August 21, 2014, we randomly assigned 388 participants to treatment; 387 received at least one dose of study medication (128 0&#xb7;5 mg semaglutide, 130 1&#xb7;0 mg semaglutide, 129 placebo). 17 (13%) of those assigned to 0&#xb7;5 mg semaglutide, 16 (12%) assigned to 1&#xb7;0 mg semaglutide, and 14 (11%) assigned to placebo discontinued treatment; the main reason for discontinuation was gastrointestinal adverse events such as nausea.

Limitations: Standard limitations apply. Check original paper for full discussion.

After a standardised breakfast, semaglutide, compared with placebo, led to a lower ad libitum energy intake during lunch (-1255&#x2009;kJ; P &#x2009;<&#x2009;.0001) and during the subsequent evening meal ( P &#x2009;=&#x2009;.0401) and snacks ( P &#x2009;=&#x2009;.0034), resulting in a 24% reduction in total energy intake across all ad libitum meals throughout the day (-3036&#x2009;kJ; P &#x2009;<&#x2009;.0001). Fasting overall appetite suppression scores were improved with semaglutide vs placebo, while nausea ratings were similar.

Limitations: Standard limitations apply. Check original paper for full discussion.

Between Jan 6, 2016, and June 22, 2016, 1201 patients were randomly assigned to treatment; of these, 301 were exposed to semaglutide 0&#xb7;5 mg, 299 to dulaglutide 0&#xb7;75 mg, 300 to semaglutide 1&#xb7;0 mg, and 299 to dulaglutide 1&#xb7;5 mg. 72 (6%) patients withdrew from the trial (22 receiving semaglutide 0&#xb7;5 mg, 13 receiving dulaglutide 0&#xb7;75 mg, 21 receiving semaglutide 1&#xb7;0 mg, and 16 receiving dulaglutide 1&#xb7;5 mg).

Limitations: No placebo control reported.

Between Dec 2, 2013, and Aug 5, 2015, we randomly assigned 1231 participants; of the 1225 included in the modified intention-to-treat analysis, 409 received semaglutide 0&#xb7;5 mg, 409 received semaglutide 1&#xb7;0 mg, and 407 received sitagliptin 100 mg. Mean baseline HbA1c was 8&#xb7;1% (SD 0&#xb7;93); at week 56, HbA1c was reduced by 1&#xb7;3% in the semaglutide 0&#xb7;5 mg group, 1&#xb7;6% in the semaglutide 1&#xb7;0 mg group, and 0&#xb7;5% with sitagliptin (estimated treatment difference vs sitagliptin -0&#xb7;77% [95% CI -0&#xb7;92 to -0&#xb7;62] with semaglutide 0&#xb7;5 mg and -1&#xb7;06% [-1&#xb7;21 to -0&#xb7;91] with semaglutide 1&#xb7;0 mg; p<0&#xb7;0001 for non-inferiority and for superiority, for both semaglutide doses vs sitagliptin).

Limitations: Standard limitations apply. Check original paper for full discussion.

Intact semaglutide in urine accounted for 3.1% of the administered dose in humans and less than 1% in rats; it was not detected in urine in monkeys. The metabolite profiles of semaglutide in humans appear to be similar to the profiles from the nonclinical species investigated.

Limitations: No placebo control reported.

Between Aug 4, 2014, and Sept 3, 2015, we randomly assigned 1089 participants to treatment; the mITT population consisted of 362 participants assigned to 0&#xb7;5 mg semaglutide, 360 to 1&#xb7;0 mg semaglutide, and 360 to insulin glargine. 49 (14%) participants assigned to 0&#xb7;5 mg semaglutide discontinued treatment prematurely, compared with 55 (15%) assigned to 1&#xb7;0 mg semaglutide, and 26 (7%) assigned to insulin glargine.

Limitations: No placebo control reported.

Baseline characteristics were comparable across treatment groups. Of the 632 randomized patients (mean age, 57.1 years [SD, 10.6]; men, 395 (62.7%); diabetes duration, 6.3 years [SD, 5.2]; body weight, 92.3 kg [SD, 16.8]; BMI, 31.7 [SD, 4.3]), 583 (92%) completed the trial.

Limitations: Standard limitations apply. Check original paper for full discussion.